
BSX · NYSE
Boston Scientific is a healthcare medical-device company that earns revenue by selling products used in clinical procedures. The supplied evidence specifically identifies the WATCHMAN left-atrial-appendage product and electrophysiology, or EP, products as important businesses, while its reported materials do not quantify their individual contributions or provide a complete segment breakdown. Customers are healthcare providers and clinicians using these devices in patient treatment. Boston Scientific reported $20.1 billion of fiscal 2025 revenue and $2.9 billion of net income, compared with $16.7 billion and $1.8 billion, respectively, in fiscal 2024.
BSX gained 0.89%, from $43.72 to $44.11 over the quoted week. The clearest company-specific pressure was Wells Fargo’s price-target reduction to $48 from $50, reported on September 23, with cyberattack impact cited as the reason. Trading was volatile: shares jumped from $43.72 on September 21 to $44.92 the next day, then fell to $43.92 by September 25, giving back most of that early advance before a modest rebound to $44.11 on September 28. The close-to-close gain therefore masks a reversal after Tuesday’s rise. The supplied evidence does not identify another company-specific catalyst for the final rebound.
Boston Scientific rose $3.03, or 6.58%, from $46.06 to $49.09 over the reported week. The advance began before the week, with the stock moving from $46.00 on July 30 to $46.73 on July 31, then extending gains to $48.43 on August 3 and $49.09 on August 4. The main company-specific catalyst was second-quarter performance: revenue grew at the high end of guidance and adjusted earnings per share exceeded expectations. Investors also responded to management’s cost-savings initiatives and future product catalysts, while an August 4 report highlighted a recent insider purchase by Director Edwar. The rally persisted despite management lowering its full-year outlook because of WATCHMAN and electrophysiology pressure.